Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
Thursday, May 17, 4:05 P.M.

CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation will be part of the 11th International Congress on Autoimmunity taking place in Lisbon, Portugal.

Presentation Details

Presentation Title: Targeting the Neonatal Fc Receptor (FcRn) for the Treatment of Pathogenic IgG Antibody Diseases

Session Title: IVIG MIMETICS: Potential Next Generation Biologics in Autoimmune Diseases

Presentation Date/Time:Saturday, May 19, 2018; 5:30 p.m. –5:50 p.m. WEST

Location: Auditorium VIII, Parallel Session

Presenter: Anthony Manning, Ph.D., Senior Vice President Research, Momenta Pharmaceuticals

The slides will be made available shortly after the presentation on the Momenta Pharmaceuticals website at: ir.momentapharma.com/events-and-presentations

The presentation will focus on a discussion of the broad potential of FcRn antagonists in rare auto- and allo-immune diseases, and describe details of the discovery and development of M281, Momenta’s anti-FcRn therapeutic. The presentation will highlight the unique design attributes of M281, including best-in-class potency and pH insensitivity achieved via proprietary somatic hypermutation technology, fully human IgG scaffold to minimize immunogenic potential, and state-of-art aglycosylation variant design to eliminate any effector function potential. Dr. Manning will present X-ray crystallographic data revealing a unique structural basis for best-in-class affinity, extensive pre-clinical pharmacology and toxicology evaluation, and Phase 1 human clinical trial data that support the potential of M281 as a best-in-class FcRn antagonist.

http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-presentation-m281-anti-fcrn